Literature DB >> 9763034

A cutaneous agranular CD2- CD4+ CD56+ "lymphoma": report of two cases and review of the literature.

J Kameoka1, R Ichinohasama, M Tanaka, I Miura, Y Tomiya, S Takahashi, M Yamada, I Ishikawa, I Kadowaki, O Sasaki, J Kimura, K Meguro, K Ooya, S Ito.   

Abstract

We report 2 cases of agranular CD2- CD4+ CD56+ non-Hodgkin lymphoma in which skin seemed to be the primary site. A 21-year-old woman's initial symptom was a skin nodule on the right cheek. She also had tumors in the nasopharynx, and the bone marrow subsequently became involved. No lymphadenopathy was present. She experienced complete remission after dose-intensified therapy with cyclophosphamide, hydroxydaunomycin, vincristine [Oncovin], and prednisone (CHOP), but the disease relapsed in the central nervous system 6 months later. An 81-year-old man experienced an 11-month history of skin nodules in the left forearm. On admission, he had a bone marrow infiltration of lymphoma cells. He died of pneumonia during chemotherapy. The malignant cells of the 2 patients had similar morphologic features, with a monocytoid nucleus and no cytoplasmic granules. The cells in both cases showed a unique phenotype: CD2-, CD3-, CD4+, CD8-, CD13-, CD14-, CD34-, CD16-, CD56+, CD57-, HLA-DR-positive. Staining for peroxidase and alpha-naphthyl butyrate esterase was negative. The T-cell receptor beta, gamma, delta, IgH, kappa, lambda genes were of germ line configurations. The DNA of Epstein-Barr virus was not detected from the bone marrow cells by polymerase chain reaction. Only 3 other cases with similar phenotypes have been reported; all had skin lesions. Although the origin of these cells remains unknown, we propose that this is a distinct clinicopathologic entity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9763034     DOI: 10.1093/ajcp/110.4.478

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

1.  Central nervous system involvement in CD4+/CD56+ hematodermic neoplasm: a report of two cases.

Authors:  Nóra Eros; Márta Marschalkó; Katalin Balassa; Bernadett Hídvégi; József Szakonyi; Sándor Ilniczky; Katalin Borka; Attila Kovács; Gyula Bottlik; Judit Hársing; Judit Csomor; Agota Szepesi; András Matolcsy; Sarolta Kárpáti; Judit Demeter
Journal:  J Neurooncol       Date:  2009-10-02       Impact factor: 4.130

2.  Expounding on the essence of epigenetic and genetic abnormalities in blastic plasmacytoid dendritic cell neoplasms.

Authors:  Lhara Lezama; Robert S Ohgami
Journal:  Haematologica       Date:  2019-04       Impact factor: 9.941

3.  A novel plasmacytoid dendritic cell line, CAL-1, established from a patient with blastic natural killer cell lymphoma.

Authors:  Takahiro Maeda; Kenn Murata; Takuya Fukushima; Kazuyuki Sugahara; Kazuto Tsuruda; Masanobu Anami; Yasuyuki Onimaru; Kunihiro Tsukasaki; Masao Tomonaga; Ryouzou Moriuchi; Hiroo Hasegawa; Yasuaki Yamada; Shimeru Kamihira
Journal:  Int J Hematol       Date:  2005-02       Impact factor: 2.490

Review 4.  Blastic Plasmacytoid Dendritic Cell Neoplasm.

Authors:  Joseph D Khoury
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

5.  Simultaneous deletion of 3'ETV6 and 5'EWSR1 genes in blastic plasmacytoid dendritic cell neoplasm: case report and literature review.

Authors:  Zhenya Tang; Guilin Tang; Sa A Wang; Xinyan Lu; Ken H Young; Carlos E Bueso-Ramos; Yesid Alvarado; L Jeffrey Medeiros; Joseph D Khoury
Journal:  Mol Cytogenet       Date:  2016-02-27       Impact factor: 2.009

Review 6.  Spontaneous Regression of Blastic Plasmacytoid Dendritic Cell Neoplasm Following Sepsis by Serratia marcescens: A Case Report and Literature Review.

Authors:  Akane Suzuki; Shori Abe; Kaori Koyama; Shinju Suzuki; Munenori Nagao; Masahiro Kobayashi; Jun Nomura; Tomomi Tsutsumi; Tomoki Takeda; Yumiko Oka; Yuko Shirota; Naruhiko Takasawa; Takao Kodera; Yoko Okitsu; Shinichiro Takahashi; Ryo Ichinohasama; Junichi Kameoka
Journal:  Intern Med       Date:  2021-03-15       Impact factor: 1.271

Review 7.  What is CD4+CD56+ malignancy and how should it be treated?

Authors:  P Reimer; T Rüdiger; D Kraemer; V Kunzmann; F Weissinger; A Zettl; H Konrad Müller-Hermelink; M Wilhelm
Journal:  Bone Marrow Transplant       Date:  2003-10       Impact factor: 5.483

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.